Curis Announces Genentech’s Initiation Of Phase II Clinical Trial In Advanced Ovarian Cancer With Hedgehog Pathway Inhibitor

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog pathway inhibitor, as a maintenance therapy for ovarian cancer patients in second or third complete remission.

More: continued here

Filed under: Cancer on December 11th, 2008